PharmAla Biotech (CSE:MDMA) is thrilled to announce the unveiling of a revolutionary Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs). This application, filed on August 20, 2021, contains compositions of MDMA and its analogs that are capable of reducing the known side effects of MDMA while still preserving its efficacy. This is a major milestone that could have a substantial impact on the future of MDMA use and treatment.
PharmAla Biotech is pushing the boundaries of innovation. With extensive in-vivo preclinical research and meetings with regulators, the company is well on its way to clinical trials and the validation of its molecular compositions. Dr Harpreet Kaur, Vice President of Research, is excited to share the results of these meetings soon, and is confident that the data will support the novelty and inventiveness of the applications. PharmAla has already established its manufacturing and regulatory prowess, and is eager to move rapidly into securing intellectual property and clinical research.
PharmAla has developed compelling evidence of the improved safety pharmacology of its ALA series of MDMA Analogs, which includes diminished hyperthermia, reduced stimulant-like effects, and cardiotoxicity. To further bolster their research, PharmAla has also formulated 3 novel compositions of 1,3-benzodioxolyl-N-methylbutanamine (MBDB) – known as the ABA series – based on preclinical animal studies conducted at the University of Arkansas School for Medical Sciences (UAMS). Both the ALA and ABA series demonstrate an improved toxicology profile and maintain their therapeutic effects.
For nearly a year and a half, PharmAla Biotech at UAMS has been conducting an in vivo research program to investigate the effects of certain compositions in behavioral and physiological models in rodents. The results have been incredibly successful, as the hypotheses have been proven accurate and novel positive features have been discovered. It is an exciting time for PharmAla Biotech, and they look forward to sharing their findings with patent offices and regulators worldwide.
PharmAla is revolutionizing the pharmaceutical industry with its cutting-edge pipeline of novel entactogenic molecule drug candidates that promise to be the best in the world. With a mission to develop innovative treatments, PharmAla is making groundbreaking strides to improve the lives of patients everywhere.
At PharmAla Biotech, we are confident that our two business lines are incredibly synergistic in the long-term. Our GMP LaNeo MDMA is making its way into new markets, and we are also making sure that our novel molecules, which are subject to successful clinical trials, will be able to be distributed within these networks. CEO Nick Kadysh is passionate about this mission and is excited for the potential this could bring.
PharmAla Biotech Holdings Inc. (CSE: MDMA) is pioneering the way forward in the psychedelics industry. Our team of dedicated regulatory experts, scientists, and biomanufacturing professionals have formed a “regulatory first” organization, with one foot in the present and one in the future. We are dedicated to alleviating the global backlog of generic, clinical-grade MDMA, and to developing novel drugs in the same class. We are the first in North America to create a cGMP MDMA value chain for the production of Active Pharmaceutical Ingredient (API) and drug product formulation. Plus, we have initiated preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules. Join us on our mission to make a real difference in the field of psychedelics.